Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could help doctors target neck cancer treatment more precisely

NCT ID NCT05055206

Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting a radioactive tracer around oropharynx tumors and using SPECT-CT scans can map lymph node drainage. Twelve patients with oropharynx cancer participated. The goal was to see if this imaging method is practical and could help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
99m-Technetium sulfur colloid
What this could lead to
If successful, this imaging technique could help doctors better decide which side of the neck needs radiation or surgery, potentially reducing unnecessary treatment.
What could go wrong
This is a very small feasibility study with only 12 participants, so results may not apply broadly. The technique is still experimental and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Sep 2021

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient has lateralized oropharyngeal carcinoma (tonsil or tongue base) not involving midline * Has squamous cell carcinoma, T1-3 tumours, with no contralateral nodes on clinical exam or axial imaging * Human papillomavirus (HPV) positive or negative * Patient should have normal organ function as per Investigator judgement * Patient is planned for definitive or adjuvant radiotherapy (RT) or chemo radiotherapy (CRT) with bilateral neck RT, or surgery * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Exclusion Criteria: * T4 tumours * Contralateral/bilateral nodal disease or node(s) \> 6cm on clinical exam or axial imaging or positron emission tomography (PET) * Primary tumour involving or crossing midline * Soft palate or posterior pharyngeal wall tumour subsites * Previous head and neck cancer * Previous radiotherapy (RT) to the head and neck * Previous neck dissection * Distant metastases * Prior invasive malignancy (except non-melanoma skin cancer) unless disease free for 3 years * Prior radiotracer allergy * Multiple primary head and neck cancers * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lateralized oropharyngeal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

oropharyngeal carcinoma oropharynx cancer oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oropharynx cancer

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 4A6, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.